氨酸激酶抑制剂在非先进的全身性巨细胞瘤中
1Division of Allergy and Clinical Immunology, Department of Internal Medicine, University of Michigan, 24 Frank Lloyd Wright Drive, PO Box 442, Suite H-2100, Ann Arbor, MI 48106-0442, USA.
Immunology and allergy clinics of North America
|September 27, 2023
概括
系统性乳腺细胞瘤 (SM) 患者的非晚期疾病往往有轻微的症状. 氨酸激酶抑制剂 (TKIs) 显示出治疗惰性系统性巨细胞瘤的严重症状的前景.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 系统性巨细胞症 (SM) 是一种罕见的疾病,其特征是巨细胞的异常积累.
- 在90%以上的MS病例中存在KIT D816V突变.
- 非高级的MS形式 (惰的MS,骨髓巨细胞瘤,燃烧的MS) 通常具有良好的预后和正常的预期寿命.
研究的目的:
- 审查目前的科学理解和临床试验数据,用于非高级系统性乳腺细胞瘤的氨酸激酶抑制剂 (TKIs).
- 讨论TKIs在管理不发症SM患者的耐火性症状中的作用.
主要方法:
- 审查当前的科学文献和临床试验数据.
- 专注于氨酸激酶抑制剂 (TKI) 针对KIT突变.
- 在非先进的全身性乳腺细胞瘤中治疗疗效和安全性的分析.
主要成果:
- 阿瓦普利提尼布已被批准用于惰性全身性巨细胞瘤 (ISM),提供了一种新的治疗选择.
- 其他几种技术知识正在临床试验中进行研究,用于非先进的SM.
- TKI可能会为患者提供缓解,持续的,严重的症状不响应抗中介药物的患者.
结论:
- 氨酸激酶抑制剂在治疗全身性巨细胞瘤,包括非高级形式的治疗中取得了重大进展.
- 进一步的研究和临床试验至关重要,以确定技术知识的作用在管理非先进的SM.
- 优化的抗介质疗法仍然至关重要,TCI为耐火病例提供了潜在的下一步.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:26Receptor Tyrosine Kinases
13.1K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
13.1K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
190
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
190
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K